Case
Project background
A client was working on a novel intervention in oncology. The intervention produced by the client had demonstrated superior efficacy and tolerable safety in phase III clinical trial in a new indication, and the client required strong value messaging as part of a global value dossier to support their application for market access in this indication.
Challenges faced
Value communication for the global value dossier needed to reflect the messaging for the clinical trial outcomes in terms of efficacy and safety benefit, the messaging for the intervention's impact on the unmet need and quality of life of patients, and the health and economic value presented in the dossier itself. A coherent and compelling value message for the new indication had to incorporate these viewpoints and align with multiple documents.